Funding Round
Salvia Bioelectronics raises €42M Series B for closed-loop migraine implant
Fierce Biotech3/31/2026·03/31/26🌐 Europe
Summary
Eindhoven-based Salvia Bioelectronics secured €42M Series B led by EQT Life Sciences, with Forbion, Gilde Healthcare, and BioGeneration Ventures. The round supports their SALVIA-1 first-in-human trial for the closed-loop cortical migraine device and development of a next-generation miniaturized form factor targeting full commercial implantation.
Why it matters
Migraine is one of the world's most disabling conditions with a 1-billion-person global prevalence and limited options for the 3-4 million people with truly refractory chronic migraine. Salvia's closed-loop approach is differentiated from existing nerve stimulation devices by sensing and responding to attack onset.
#Bioelectronic Medicine#Chronic Pain#Closed-Loop#Neurostimulation
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in